In a systematic review and meta-analysis, Dafni et al. (2019) showed that combination of chemotherapy with anti-PD-1/PD-L1 ICBs enhanced treatment efficacy as a first-line treatment in NSCLC patients compared to using chemotherapy alone [108]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.